Regenerative Market Position Solsys Medical as a provider of regenerative wound care solutions with TheraSkin cellular therapies and TheraGauze moisture-controlled dressings to expand into hospital, long-term care, and surgical wound centers seeking advanced biologic grafts and non-adherent, moisture-balanced dressings.

CMS Pass-Through Leverage the CMS pass-through status secured for TheraSkin to accelerate national reimbursement discussions, enabling faster adoption in wound care clinics and post-acute care facilities and reducing financial barriers for customers.

Strategic Partnerships Highlight established distribution and collaboration with Skin and Wound Allograft Institute and LifeNet Health to support rapid nationwide scaling; propose co-marketing and bundled offerings with regenerative medicine providers and grafting centers.

Expansion Readiness Capitalize on the revenue growth trajectory post-acquisition by Misonix and aim at mid-market hospitals, multi-site wound care programs, and specialty surgical centers that require biologic dressings and moisture-rebalancing technologies.

Tech & Education Offer sales plays that emphasize SMRT technology benefits and non-maceration wound healing, supported by clinical education, case studies, and payer value propositions to drive adoption among wound care specialists, plastic surgery, and orthopedics.